Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Comparison of the Efficacy in Clinical Trials Versus Effectiveness in the Real-World of Treatments for Multiple Myeloma: A Population-Based Cohort Study

Alissa Visram, Kelvin KW Chan, Hsien Seow, Gregory Pond, Ana Gayowsky, Arleigh McCurdy, Irwindeep Sandhu, Christopher P. Venner, Guido Lancman, Amaris Balitsky, Robert Bruins, Shaji Kunnathu Kumar, Rafael Fonseca, Hira Mian

Blood (2023) 142 (Supplement 1): 541.

https://doi.org/10.1182/blood-2023-189506

Published: 2023

Journal Articles

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 614–616.

https://doi.org/10.1182/blood-2022-165646

Published: 2022

Journal Articles

Extramedullary Relapse Post CAR-T

Shambavi Richard, Guido Lancman, Adriana Rossi, Ajai Chari, Samir Parekh, Larysa Sanchez, Cesar Rodriguez, Hearn J. Cho, Joshua Richter, Santiago Thibaud, Kiah Purcell, Elizabeth Aronson, Daniel Verina, Juliet Escalon, Karen Louw, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 4301–4302.

https://doi.org/10.1182/blood-2022-170119

Published: 2022

Journal Articles

Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Guido Lancman, Kian Parsa, Cesar Rodriguez, Joshua Richter, Hearn J. Cho, Samir Parekh, Shambavi Richard, Adriana Rossi, Larysa Sanchez, Santiago Thibaud, Sundar Jagannath, Ajai Chari

Blood (2022) 140 (Supplement 1): 10073–10074.

https://doi.org/10.1182/blood-2022-163733

Published: 2022

Journal Articles

Immune Recovery Post BCMA CAR-T: Implications for Infection Prophylaxis and Vaccinations

Shambavi Richard, Guido Lancman, Santiago Thibaud, Ajai Chari, Samir Parekh, Adriana Rossi, Hearn J. Cho, Larysa Sanchez, Joshua Richter, Cesar Rodriguez, Elizabeth Aronson, Karen Louw, Kiah Purcell, Daniel Verina, Juliet Escalon, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 7444–7446.

https://doi.org/10.1182/blood-2022-170404

Published: 2022

Journal Articles

Timing and Nature of Infections in Multiple Myeloma Patients Treated with Anti-BCMA CAR-T Cells

Guido Lancman, Margaret Shyu, Megan Metzger, Kian Parsa, Hearn J. Cho, Samir Parekh, Joshua Richter, Cesar Rodriguez, Adriana Rossi, Larysa Sanchez, Santiago Thibaud, Sundar Jagannath, Ajai Chari, Shambavi Richard

Blood (2022) 140 (Supplement 1): 7198–7199.

https://doi.org/10.1182/blood-2022-163757

Published: 2022

Journal Articles

Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T

Oliver Van Oekelen, Tarek H. Mouhieddine, Darren Pan, Megan Metzger, Sarita Agte, Adolfo Aleman, David T. Melnekoff, Guido Lancman, Alessandro Lagana, Shambavi Richard, Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2021) 138 (Supplement 1): 2704.

https://doi.org/10.1182/blood-2021-152243

Published: 2021

Journal Articles

Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)

Tarek H. Mouhieddine, Oliver Van Oekelen, Darren Pan, Sarita Agte, Adolfo Aleman, David T. Melnekoff, Guido Lancman, Santiago Thibaud, Larysa Sanchez, Shambavi Richard, Joshua Richter, Hearn Jay Cho, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2021) 138 (Supplement 1): 821.

https://doi.org/10.1182/blood-2021-151585

Published: 2021

Journal Articles

Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab

Guido Lancman, MD, Dahniel Sastow, BA, Minira Aslanova, MD, Erin Moshier, MS, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Samir Parekh, MD, Shambavi Richard, MD, Joshua Richter, MD, Larysa Sanchez, MD, Ajai Chari, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140056

Published: 2020

Journal Articles

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Douglas Tremblay, MD, Rafael Madero-Marroquin, MD, Guido Lancman, MD, Alexander Coltoff, MD, Jonathan Feld, MD, Jessica Caro, MD, Nicole Zubizarreta, MPH, Marina Kremyanskaya, Alla Keyzner, MD, Michal Bar-Natan, MD, Shyamala C. Navada, MD, Lewis R. Silverman, Janice L. Gabrilove, MD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 5102.

https://doi.org/10.1182/blood-2019-123288

Published: 2019

Journal Articles

Impact of Primary Antibacterial Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients

Jessica Caro, MD, Erin Moshier, MS, Douglas Tremblay, MD, Alexander Coltoff, MD, Guido Lancman, MD, Meenakshi Rana, MD, John Mascarenhas, MD, Samantha Jacobs, MD

Blood (2019) 134 (Supplement_1): 3849.

https://doi.org/10.1182/blood-2019-123435

Published: 2019

Journal Articles

The Effect of JAK 1/2 Inhibitors on Outcomes of Allogeneic Stem Cell Transplantation for Patients with Myelofibrosis

Guido Lancman, MD, Kathleen Miller, MD, Shuli Li, PhD, Vincent T. Ho, MD, Amir T. Fathi, MD, Yi-Bin Chen, MD, Alla Keyzner, MD, Douglas Tremblay, MD, Anita Geevarghese, MD, Prapti Chatterjee, MD, Ronald Hoffman, MD, John Mascarenhas, MD, Gabriela S. Hobbs, MD

Blood (2018) 132 (Supplement 1): 5784.

https://doi.org/10.1182/blood-2018-99-112769

Published: 2018

Journal Articles

Impact of Transfusion Dependence on Outcomes of Patients with Acute Myeloid Leukemia (AML) Evolving from Myeloproliferative Neoplasms (MPNs)

Andrew M. Brunner, MD, Guido Lancman, Ronald Hoffman, MD, John Mascarenhas, MD, Gabriela S. Hobbs, MD

Blood (2017) 130 (Supplement 1): 2914.

https://doi.org/10.1182/blood.V130.Suppl_1.2914.2914

Published: 2017

NARROW

Comparison of the Efficacy in Clinical Trials Versus Effectiveness in the Real-World of Treatments for Multiple Myeloma: A Population-Based Cohort Study

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Extramedullary Relapse Post CAR-T

Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Immune Recovery Post BCMA CAR-T: Implications for Infection Prophylaxis and Vaccinations

Timing and Nature of Infections in Multiple Myeloma Patients Treated with Anti-BCMA CAR-T Cells

Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T

Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)

Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Impact of Primary Antibacterial Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients

The Effect of JAK 1/2 Inhibitors on Outcomes of Allogeneic Stem Cell Transplantation for Patients with Myelofibrosis

Impact of Transfusion Dependence on Outcomes of Patients with Acute Myeloid Leukemia (AML) Evolving from Myeloproliferative Neoplasms (MPNs)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only